A 44 year-old Latin American female with history of ADHD presents to psychiatric medication follow up requesting to discontinue guanfacine 2mg BID, as she is concerned about potential medication interactions that could occur with antihypertensives prescribed by her primary care doctor. Upon confirmation of risk for med/med interaction, the PMHNP: a. Discontinues guanfacine immediately, due to current acute risk of hypotension and patient's subjective complaints of dizziness b. Lowers the dose of guanfacine to 1mg to be dosed at night to address sedation c. Establishes a plan for tapering guanfacine slowly, to ensure hyperactivity returns slowly d. Discontinues guanfacine gradually due to risk of rebound hypotension
1) Discontinues guanfacine immediately, due to current acute risk of hypotension and patient's subjective complaints of dizziness
2) Lowers the dose of guanfacine to 1mg to be dosed at night to address sedation
3) Establishes a plan for tapering guanfacine slowly, to ensure hyperactivity returns slowly
4) Discontinues guanfacine gradually due to risk of rebound hypotension